Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002515 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002515: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00002515 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002515, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with thiotepa, carboplatin, and topotecan followed by bone marrow transplantation in treating patients who have metastatic or progressive rare cancer.
Interventions
- DRUG carboplatin
- BIOLOGICAL filgrastim
- DRUG thiotepa
- DRUG topotecan hydrochloride
- PROCEDURE autologous bone marrow transplantation
Trial Details
| Field | Value |
|---|---|
| Start Date | 1992-10 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
What the finished NCT00002515 record still lists
NCT00002515 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00002515 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002515 about?
NCT00002515 is a clinical study titled "Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination che...
What is the current status of trial NCT00002515?
This trial is currently completed. It is a Phase 2 study. The study started on 1992-10. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00002515?
The interventions under investigation include: carboplatin (DRUG), filgrastim (BIOLOGICAL), thiotepa (DRUG), topotecan hydrochloride (DRUG), autologous bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00002515?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia